Total returns on $1000
1Y
- 3M
- 6M
- 1Y
- 3Y
- 5Y
Fund/benchmark | Change | |
---|---|---|
Price | RTW Biotech Opportunities Ltd (Ordinary Share) | +27.59% |
NAV | RTW Biotech Opportunities Ltd (Ordinary Share) | +31.97% |
Morningstar's Benchmark | Russell 2000 Biotech Growth [50.00%]; Nasdaq Biotechnology Index [50.00%] | -- |
Announcements
- CORXEL Announces Acceptance of NDA for Aficamten
- Monthly Valuation Update and Factsheet
- New Investment in Series C Round of Evommune, Inc.
- RTW Biotech Opportunities’ 5th Anniversary
- Monthly Valuation Update and Factsheet Replacement
- Launch of Obesity Company Kailera Therapeutics
- New Investment in Aktis Oncology
- BioAge Labs completes $198 million IPO
- GBP quote for the share class to cease
- Monthly Valuation Update and Factsheet
More ▼
Key statistics
As of last trade RTW Biotech Opportunities Ltd (RTW:LSE) traded at 1.46, -15.61% below its 52-week high of 1.73, set on Jul 31, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Shares outstanding | 335.71m |
---|---|
Market cap | 496.86m USD |
Total assets | 651.28m USD |
Total expense ratio | 1.97% |
High | 1.48 |
Low | 1.46 |
Previous close | 1.48 |
Average volume | 813.85k |
---|---|
YTD Change | +4.10% |
Beta | 0.6435 |
Diluted NAV (est) | 1.94 |
Diluted NAV (last pub) | 1.94 |
Premium/Discount | -23.71% |
Net Gearing | 0.00% |
Data delayed at least 20 minutes, as of Nov 22 2024 11:09 GMT.
More ▼